The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.
Translational Immunotherapy Team, Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, United Kingdom.
Elife. 2020 Sep 10;9:e58374. doi: 10.7554/eLife.58374.
SOX11 is an embryonic mammary epithelial marker that is normally silenced prior to birth. High levels in breast tumours are significantly associated with distant metastasis and poor outcome in breast cancer patients. Here, we show that SOX11 confers distinct features to ER-negative DCIS.com breast cancer cells, leading to populations enriched with highly plastic hybrid epithelial/mesenchymal cells, which display invasive features and alterations in metastatic tropism when xenografted into mice. We found that SOX11+DCIS tumour cells metastasize to brain and bone at greater frequency and to lungs at lower frequency compared to cells with lower SOX11 levels. High levels of SOX11 leads to the expression of markers associated with mesenchymal state and embryonic cellular phenotypes. Our results suggest that SOX11 may be a potential biomarker for breast tumours with elevated risk of developing metastases and may require more aggressive therapies.
SOX11 是一种胚胎期乳腺上皮标志物,通常在出生前被沉默。在乳腺癌肿瘤中高水平表达与远处转移和不良预后显著相关。在这里,我们表明 SOX11 赋予 ER 阴性 DCIS.com 乳腺癌细胞独特的特征,导致富含高度可塑性的混合上皮/间充质细胞的群体,这些细胞在异种移植到小鼠中时表现出侵袭特征和转移倾向的改变。我们发现,与 SOX11 水平较低的细胞相比,SOX11+DCIS 肿瘤细胞转移到大脑和骨骼的频率更高,转移到肺部的频率更低。SOX11 水平升高导致表达与间充质状态和胚胎细胞表型相关的标志物。我们的结果表明,SOX11 可能是一种具有升高转移风险的乳腺癌的潜在生物标志物,可能需要更积极的治疗。